Molecular Therapy · 2019 · 61 citations · 20 references
PharmacyOncologyPharmacologyCancer PharmacologyMolecular VirologyVirologyAntiviral PharmacotherapyAntiviral TherapyOncogenic VirusesOncolytic Virus TherapyPharmacokinetics In Children With CancerAntiviral Safety AssessmentIntratumoral AdministrationIntravenous Injection SafetyOncolytic Viral TherapyRefractory Solid TumorsSerious Adverse EventsSystemic Virus AdministrationViral Safety Assessment
iu) of Seprehvir via the peripheral vein, monitored adverse events, and measured tumor responses by imaging. We monitored HSV-1 serology as well as viremia and shedding by PCR and culture. We administered a single dose of Seprehvir to seven patients and multiple doses to two patients. We did not observe any dose-limiting toxicities. All five HSV-1 seronegative patients seroconverted by day 28. Four of nine patients had detectable HSV-1 genomes in peripheral blood appearing on day +4 consistent with de novo virus replication. Two patients had stable disease in response to Seprehvir. Intravenous Seprehvir is well tolerated without viral shedding in children and young adults with late-stage cancer. Viremia consistent with virus replication holds promise for future Seprehvir studies at higher doses and/or in combination with other anti-neoplastic therapies.
20
Intravenous delivery of a multi-mechanistic cancer-targeted oncolytic poxvirus in humans
Caroline J. Breitbach, James M. Burke, Derek J. Jonker et al. · Nature · 2011 · 550 citations
Pharmacy, Oncology, Pharmaceutics +12
Julia Glade Bender, Alice Lee, Joel M. Reid et al. · Journal of Clinical Oncology · 2013 · 164 citations · Full text
Pharmacy, Oncology, Pharmacology +17